AbbVie Receives FDA Approval for New BPDCN Treatment, Expanding Its Oncology Pipeline
AbbVie Inc. (ABBV) received FDA approval for DECNUPAZ to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer. The treatment showed strong clinical responses in trials and could expand ABBV's oncology portfolio, potentially boosting its market position.
Tickers: $ABBV
Topics: bpdcn treatment hepatitis c oncology pharmaceuticals